

xCures Announces Issuance of Groundbreaking Patent

USPTO awards patent for AI tech enabling virtual trials, enhancing clinical decisions through continuous learning from patient experiences.

OAKLAND, CALIFORNIA, UNITED STATES, March 7, 2024

/EINPresswire.com/ -- xCures, Inc., a leader in health technology, is proud to announce that the U.S. Patent and Trademark Office (USPTO) has officially issued Patent No. 11,887,738, a

landmark achievement in biomedical decision-making. This patent marks a significant milestone in the company's journey to transform the value of healthcare data using artificial intelligence (AI) and deliver on the promise of precision medicine.



“

It is just the first of many patent-pending innovations in our pipeline”

Mark Shapiro, Chief Operating Officer - xCures Inc.

The newly patented technology, titled "Platforms for Conducting Virtual Trials," introduces a novel platform for capturing clinical cases and expert-derived treatment rationales using AI to facilitate biomedical decision-making, which can include virtual clinical trials that continuously learn from the experiences of all patients, on all treatments and all the time. Algorithms such as Bayesian machine learning methods can be applied to coordinate

such virtual trials. This invention demonstrates xCures' vision for transforming US healthcare data into continuous, real-time, regulatory-grade data that can improve care, drive innovation, and accelerate the development of new treatments.

"We're incredibly excited about this patent. The USPTO recognized our innovative work in AI-enabled learning systems using medical records plus AI to create patient case summaries, using natural language processing to create knowledge bases that support treatment selection, leveraging machine learning for personalized treatment recommendations, incorporating expert human feedback to refine algorithms, and continuous improvements via calibration from real-world outcomes data. It is just the first of many patent pending innovations in our pipeline," said

Mark Shapiro, Chief Operating Officer at xCures.

With the issuance of this patent, xCures solidifies its position at the forefront of health data and technology. The company is dedicated to leveraging this patented technology to enable stakeholders across the healthcare continuum to implement platforms that collect, aggregate, organize, and structure healthcare data. This approach enables continuous learning from the treatment of all patients using an AI-based platform.

The patent can be found at <https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11887738>.

For more information about xCures and its innovative solutions, visit www.xcures.com.

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient's fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com or visit <http://www.xcures.com>.

Patrick van der Valk

xCures Inc

pvandervalk@xcures.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[TikTok](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/694029173>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.